An Exploratory, Open-Label Study of Vedolizumab (Anti-alpha4beta7 Antibody) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption
Phase of Trial: Phase I
Latest Information Update: 02 Apr 2018
At a glance
- Drugs Vedolizumab (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 21 Apr 2017 Planned number of patients changed from 20 to 40.
- 29 Jul 2016 Status changed from not yet recruiting to recruiting.
- 09 Jun 2016 New trial record